Dendreon names new CEO; Agilvax lands $2M in Series A; Merck's Zostavax effective after chemo;

> Dendreon ($DNDN) has appointed retired biotech exec W. Thomas Amick as its new CEO. Story

> New Mexico-based Agilvax has scored $2 million in Series A funding to develop its virus-like particle technology. Report

> Merck's ($MRK) shingles vaccine Zostavax remains effective after chemotherapy, a study found. Release

> PaxVax has named Jonathan Klock as its North American sales and marketing VP and Jeremy Gowler as its VP of global marketing. Release

> GeoVax has entered a clinical development license agreement with Valneva for its HIV/AIDS vaccines. Release

> The NIH has awarded $3.5 million in grants to Profectus BioSciences for HIV-related vaccine development. More

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.